Skip to main content
Erschienen in: Die Urologie 10/2021

21.06.2021 | Hodentumoren | Übersichten

Diagnostische Marker in der Urologie

verfasst von: Dr. med. Marie C. Hupe, Marie C. Hempel, Dr. med. Severin Rodler, Dr. rer. medic. Maria Frantzi, Professor Dr. Dr Harald Mischak, Professor Dr. med. Axel S. Merseburger, Professor Dr. med. Christian G. Stief, Dr. med. Michael Chaloupka

Erschienen in: Die Urologie | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Biomarker können die Diagnostik maligner Erkrankungen ergänzen. Im Zuge der modernen individualisierten Krebstherapie haben Risikostratifizierung, individuelle Prognose und nicht-invasives Monitoring an Bedeutung gewonnen. In den letzten Jahren ist eine Vielzahl an Biomarkern und zugehöriger Testverfahren hierfür entwickelt worden. Der folgende Übersichtsartikel fasst die jüngsten Entwicklungen bezüglich der Verwendung von Biomarkern in der Diagnostik urologischer Krebserkrankungen zusammen.
Literatur
1.
Zurück zum Zitat Califf RM (2018) Biomarker definitions and their applications. Exp Biol Med 243:213–221CrossRef Califf RM (2018) Biomarker definitions and their applications. Exp Biol Med 243:213–221CrossRef
2.
Zurück zum Zitat Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, , AWMF): Interdisziplininäre Leitlinie der Qualität S3 zur Führerkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinom. 2019. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, , AWMF): Interdisziplininäre Leitlinie der Qualität S3 zur Führerkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinom. 2019.
3.
Zurück zum Zitat Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (2018) Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA 319:1914–1931CrossRefPubMed Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (2018) Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA 319:1914–1931CrossRefPubMed
4.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S et al (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629PubMedCrossRef Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S et al (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629PubMedCrossRef
5.
Zurück zum Zitat Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K et al (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60:70–98PubMedCrossRef Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K et al (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60:70–98PubMedCrossRef
6.
Zurück zum Zitat Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL et al (2011) A multicenter study of [‑2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650–1655PubMedPubMedCentralCrossRef Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL et al (2011) A multicenter study of [‑2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650–1655PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V et al (2013) Clinical performance of serum prostate-specific antigen isoform [‑2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112:313–321PubMedCrossRef Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V et al (2013) Clinical performance of serum prostate-specific antigen isoform [‑2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112:313–321PubMedCrossRef
8.
Zurück zum Zitat Braun K, Sjoberg DD, Vickers AJ, Lilja H, Bjartell AS (2016) A four-kallikrein panel predicts high-grade cancer on biopsy: independent validation in a community cohort. Eur Urol 69:505–511PubMedCrossRef Braun K, Sjoberg DD, Vickers AJ, Lilja H, Bjartell AS (2016) A four-kallikrein panel predicts high-grade cancer on biopsy: independent validation in a community cohort. Eur Urol 69:505–511PubMedCrossRef
9.
Zurück zum Zitat Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H et al (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69:532–535PubMedCrossRef Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H et al (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69:532–535PubMedCrossRef
10.
Zurück zum Zitat Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J (2013) PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Urol Oncol 31:1522–1526PubMedCrossRef Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J (2013) PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Urol Oncol 31:1522–1526PubMedCrossRef
11.
Zurück zum Zitat Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44:8–15 (discussion 15–6,)PubMedCrossRef Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44:8–15 (discussion 15–6,)PubMedCrossRef
12.
Zurück zum Zitat Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ et al (2016) Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 70:740–748PubMedCrossRef Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ et al (2016) Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 70:740–748PubMedCrossRef
13.
Zurück zum Zitat Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J et al (2016) Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 70:45–53PubMedCrossRef Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J et al (2016) Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 70:45–53PubMedCrossRef
14.
Zurück zum Zitat Fredsoe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Hoyer S, Borre M, Orntoft TF, Sorensen KD (2018) Diagnostic and prognostic microRNA Biomarkers for prostate cancer in cell-free urine. Eur Urol Focus 4:825–833PubMedCrossRef Fredsoe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Hoyer S, Borre M, Orntoft TF, Sorensen KD (2018) Diagnostic and prognostic microRNA Biomarkers for prostate cancer in cell-free urine. Eur Urol Focus 4:825–833PubMedCrossRef
15.
Zurück zum Zitat Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, Polley R, Schmidt T, Schofer W, Zurbig P, Good DM et al (2008) Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2:556–570PubMedPubMedCentralCrossRef Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, Polley R, Schmidt T, Schofer W, Zurbig P, Good DM et al (2008) Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2:556–570PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Frantzi M, Gomez Gomez E, Pedregosa BA, Valero RJ, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H et al (2019) CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. Br J Cancer 120:1120–1128PubMedPubMedCentralCrossRef Frantzi M, Gomez Gomez E, Pedregosa BA, Valero RJ, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H et al (2019) CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. Br J Cancer 120:1120–1128PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Connell SP, Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG et al (2019) A four-group urine risk classifier for predicting outcome in prostate cancer patients. BJU Int 124:609–620PubMedCentralCrossRef Connell SP, Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG et al (2019) A four-group urine risk classifier for predicting outcome in prostate cancer patients. BJU Int 124:609–620PubMedCentralCrossRef
18.
Zurück zum Zitat Liu RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, Commisso K, Klotz L, Loblaw A, Liu SK, Vesprini D, Fleshner NE et al (2018) Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance. J Urol 199:1475–1481PubMedCrossRef Liu RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, Commisso K, Klotz L, Loblaw A, Liu SK, Vesprini D, Fleshner NE et al (2018) Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance. J Urol 199:1475–1481PubMedCrossRef
19.
20.
Zurück zum Zitat Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N’Dow J, Nabi G, Cook J, Vale L (2010) Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 14:1–331, iii–ivPubMedCrossRef Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N’Dow J, Nabi G, Cook J, Vale L (2010) Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 14:1–331, iii–ivPubMedCrossRef
21.
Zurück zum Zitat Dogan C, Pelit ES, Yildirim A, Zemheri IE, Canakci C, Basok EK, Caskurlu T (2013) The value of the NMP22 test for superficial bladder cancer diagnosis and follow-up. Turk J Urol 39:137–142PubMedPubMedCentralCrossRef Dogan C, Pelit ES, Yildirim A, Zemheri IE, Canakci C, Basok EK, Caskurlu T (2013) The value of the NMP22 test for superficial bladder cancer diagnosis and follow-up. Turk J Urol 39:137–142PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Raitanen MP, FinnBladder G (2008) The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 26:45–50PubMedCrossRef Raitanen MP, FinnBladder G (2008) The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 26:45–50PubMedCrossRef
23.
Zurück zum Zitat Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, Pansadoro V, Sternberg CN, Boccon-Gibod L, Ravery V et al (1999) Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 45:472–477PubMed Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, Pansadoro V, Sternberg CN, Boccon-Gibod L, Ravery V et al (1999) Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 45:472–477PubMed
24.
Zurück zum Zitat Batista R, Vinagre J, Prazeres H, Sampaio C, Peralta P, Conceicao P, Sismeiro A, Leao R, Gomes A, Furriel F et al (2019) Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive multicenter study. Front Genet 10:1237PubMedPubMedCentralCrossRef Batista R, Vinagre J, Prazeres H, Sampaio C, Peralta P, Conceicao P, Sismeiro A, Leao R, Gomes A, Furriel F et al (2019) Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive multicenter study. Front Genet 10:1237PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Rodriguez Pena MDC, Springer SU, Taheri D, Li L, Tregnago AC, Eich ML, Eltoum IA, VandenBussche CJ, Papadopoulos N, Kinzler KW et al (2020) Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. Virchows Arch 476:423–429PubMedCrossRef Rodriguez Pena MDC, Springer SU, Taheri D, Li L, Tregnago AC, Eich ML, Eltoum IA, VandenBussche CJ, Papadopoulos N, Kinzler KW et al (2020) Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. Virchows Arch 476:423–429PubMedCrossRef
26.
Zurück zum Zitat Witjes JA, Morote J, Cornel EB, Gakis G, van Valenberg FJP, Lozano F, Sternberg IA, Willemsen E, Hegemann ML, Paitan Y et al (2018) Performance of the bladder epicheck methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur Urol Oncol 1:307–313PubMedCrossRef Witjes JA, Morote J, Cornel EB, Gakis G, van Valenberg FJP, Lozano F, Sternberg IA, Willemsen E, Hegemann ML, Paitan Y et al (2018) Performance of the bladder epicheck methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur Urol Oncol 1:307–313PubMedCrossRef
28.
Zurück zum Zitat O’Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, Harvey J, Toro T, Giles N, Luxmanan C et al (2012) A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 188:741–747PubMedCrossRef O’Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, Harvey J, Toro T, Giles N, Luxmanan C et al (2012) A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 188:741–747PubMedCrossRef
29.
Zurück zum Zitat Lotan Y, O’Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, Guilford P, Luxmanan C, Suttie J, Crist H et al (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol 35:531.e15–531.e22CrossRef Lotan Y, O’Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, Guilford P, Luxmanan C, Suttie J, Crist H et al (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol 35:531.e15–531.e22CrossRef
30.
Zurück zum Zitat Valenberg F, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK et al (2021) Validation of an mRNA-based urine test for the detection of bladder cancer in patients with haematuria. Eur Urol Onco 4:93–101CrossRef Valenberg F, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK et al (2021) Validation of an mRNA-based urine test for the detection of bladder cancer in patients with haematuria. Eur Urol Onco 4:93–101CrossRef
31.
Zurück zum Zitat Valenberg F, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK et al (2019) Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur Urol 75:853–860PubMedCrossRef Valenberg F, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK et al (2019) Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur Urol 75:853–860PubMedCrossRef
32.
Zurück zum Zitat Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V (2017) Renal cell carcinoma. Nat Rev Dis Primers 3:17009PubMedPubMedCentralCrossRef Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V (2017) Renal cell carcinoma. Nat Rev Dis Primers 3:17009PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Morrissey JJ, Mellnick VM, Luo J, Siegel MJ, Figenshau RS, Bhayani S, Kharasch ED (2015) Evaluation of urine aquaporin‑1 and perilipin‑2 concentrations as biomarkers to screen for renal cell carcinoma: a prospective cohort study. JAMA Oncol 1:204–212PubMedPubMedCentralCrossRef Morrissey JJ, Mellnick VM, Luo J, Siegel MJ, Figenshau RS, Bhayani S, Kharasch ED (2015) Evaluation of urine aquaporin‑1 and perilipin‑2 concentrations as biomarkers to screen for renal cell carcinoma: a prospective cohort study. JAMA Oncol 1:204–212PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Zhang L, Jiang H, Xu G, Chu N, Xu N, Wen H, Gu B, Liu J, Mao S, Na R et al (2016) iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma. Biosci Trends 10:210–219PubMedCrossRef Zhang L, Jiang H, Xu G, Chu N, Xu N, Wen H, Gu B, Liu J, Mao S, Na R et al (2016) iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma. Biosci Trends 10:210–219PubMedCrossRef
35.
Zurück zum Zitat Smith CG, Moser T, Mouliere F, Field-Rayner J, Eldridge M, Riediger AL, Chandrananda D, Heider K, Wan JCM, Warren AY et al (2020) Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Med 12:23PubMedPubMedCentralCrossRef Smith CG, Moser T, Mouliere F, Field-Rayner J, Eldridge M, Riediger AL, Chandrananda D, Heider K, Wan JCM, Warren AY et al (2020) Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Med 12:23PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Murray MJ, Huddart RA, Coleman N (2016) The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol 13:715–725PubMedCrossRef Murray MJ, Huddart RA, Coleman N (2016) The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol 13:715–725PubMedCrossRef
37.
Zurück zum Zitat Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, Stephenson AJ, Vaughn DJ, Cosby R, Hayes DF et al (2010) American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 28:3388–3404PubMedCrossRef Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, Stephenson AJ, Vaughn DJ, Cosby R, Hayes DF et al (2010) American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 28:3388–3404PubMedCrossRef
38.
Zurück zum Zitat Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR, Daneshmand S, Protheroe A et al (2015) Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 33:51–57PubMedCrossRef Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR, Daneshmand S, Protheroe A et al (2015) Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 33:51–57PubMedCrossRef
39.
Zurück zum Zitat Curreri SA, Fung C, Beard CJ (2015) Secondary malignant neoplasms in testicular cancer survivors. Urol Oncol 33:392–398PubMedCrossRef Curreri SA, Fung C, Beard CJ (2015) Secondary malignant neoplasms in testicular cancer survivors. Urol Oncol 33:392–398PubMedCrossRef
40.
Zurück zum Zitat Novotny GW, Belling KC, Bramsen JB, Nielsen JE, Bork-Jensen J, Almstrup K, Sonne SB, Kjems J, Rajpert-De Meyts E, Leffers H (2012) MicroRNA expression profiling of carcinoma in situ cells of the testis. Endocr Relat Cancer 19:365–379PubMedCrossRef Novotny GW, Belling KC, Bramsen JB, Nielsen JE, Bork-Jensen J, Almstrup K, Sonne SB, Kjems J, Rajpert-De Meyts E, Leffers H (2012) MicroRNA expression profiling of carcinoma in situ cells of the testis. Endocr Relat Cancer 19:365–379PubMedCrossRef
41.
Zurück zum Zitat Murray MJ, Nicholson JC, Coleman N (2015) Biology of childhood germ cell tumours, focussing on the significance of microRNAs. Andrology 3:129–139PubMedCrossRef Murray MJ, Nicholson JC, Coleman N (2015) Biology of childhood germ cell tumours, focussing on the significance of microRNAs. Andrology 3:129–139PubMedCrossRef
42.
Zurück zum Zitat Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R et al (2019) Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol 37:1412–1423PubMedPubMedCentralCrossRef Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R et al (2019) Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol 37:1412–1423PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, O’Neil B, Maughan BL, Chi K, So A et al (2019) Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum. J Clin Oncol 37:3090–3098PubMedPubMedCentralCrossRef Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, O’Neil B, Maughan BL, Chi K, So A et al (2019) Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum. J Clin Oncol 37:3090–3098PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Touloupidis S, Zisimopoulos A, Giannakopoulos S, Papatsoris AG, Kalaitzis C, Thanos A (2007) Clinical usage of the squamous cell carcinoma antigen in patients with penile cancer. Int J Urol 14:174–176PubMedCrossRef Touloupidis S, Zisimopoulos A, Giannakopoulos S, Papatsoris AG, Kalaitzis C, Thanos A (2007) Clinical usage of the squamous cell carcinoma antigen in patients with penile cancer. Int J Urol 14:174–176PubMedCrossRef
45.
Zurück zum Zitat Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ (2008) The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer. J Urol 180:2019–2023PubMedCrossRef Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ (2008) The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer. J Urol 180:2019–2023PubMedCrossRef
46.
Zurück zum Zitat Ornellas P, Ribeiro-Carvalho MM, Ornellas AA, Scherrer L, Koifman L, Magni F, Ornellas MH, Alves G (2017) Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis. Urol Oncol 35:545.e13–545.e18CrossRef Ornellas P, Ribeiro-Carvalho MM, Ornellas AA, Scherrer L, Koifman L, Magni F, Ornellas MH, Alves G (2017) Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis. Urol Oncol 35:545.e13–545.e18CrossRef
Metadaten
Titel
Diagnostische Marker in der Urologie
verfasst von
Dr. med. Marie C. Hupe
Marie C. Hempel
Dr. med. Severin Rodler
Dr. rer. medic. Maria Frantzi
Professor Dr. Dr Harald Mischak
Professor Dr. med. Axel S. Merseburger
Professor Dr. med. Christian G. Stief
Dr. med. Michael Chaloupka
Publikationsdatum
21.06.2021
Verlag
Springer Medizin
Erschienen in
Die Urologie / Ausgabe 10/2021
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-021-01568-8

Weitere Artikel der Ausgabe 10/2021

Die Urologie 10/2021 Zur Ausgabe

Termine

Termine

GeSRU

GeSRU

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.